Article Correctness Is Author's Responsibility: Researchers launch study to assess safety of PrEP and dapivirine ring in pregnant women

(Microbicide Trials Network) A woman, eight-months pregnant, is the first participant enrolled into a study of the safety of two HIV prevention approaches during pregnancy -- the monthly dapivirine vaginal ring, currently under regulatory review, and Truvada, taken daily, also known as PrEP, which is already approved. Pregnancy is a time of heightened HIV risk. The study is the first of the ring in pregnant women and will provide more insight about the safety of Truvada as PrEP.